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Nitric oxide (NO) has been shown to possess
many vasoprotective properties. These include inhi-
bition of platelet and leukocyte adherence to a site of
vascular injury, inhibition of vascular smooth muscle
cell (VSMC) proliferation and migration, stimula-
tion of endothelial cell growth, and inhibition of
endothelial cell apoptosis.1-7 Of these properties,
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inhibition of VSMC proliferation may be one of the
dominant mechanisms by which NO limits intimal
hyperplasia after arterial injury. We and other authors
have shown that NO upregulates the expression of
the cyclin-dependent kinase (cdk) inhibitor p21 in
VSMCs.8,9 p21 is a universal inhibitor of the cell
cycle,10 inhibiting a broad range of cyclins and cdks,
both of which are necessary for the normal progres-
sion of the cell cycle. NO upregulation of p21 is one
mechanism by which NO inhibits VSMC prolifera-
tion and limits intimal hyperplasia after vascular injury.
The ubiquitin-proteasome pathway is one mech-
anism used by cells to degrade proteins designated
for removal. Unnecessary or senescent proteins are
phosphorylated by kinases, and this signal results in
the attachment of polyubiquitin chain(s) to lysine
residues on the substrate.11 Ubiquination then
allows for the recognition of these targeted proteins
by the 26S proteasome for subsequent proteolytic
degradation. The specific kinases involved in phos-
phorylating the substrate remain mostly unidenti-
fied. However, the addition of ubiquitin to such
moieties is mediated by the coordinated effort of the
ubiquitin activating (E1), conjugating (E2), and li-
gase (E3) enzymes. Many of the cell cycle proteins,
including the cdk inhibitors, are regulated in a large
part by the ubiquitin-proteasome pathway.11 The
second-to-second changes necessary to drive the cell
cycle from G0/G1 to synthesis (S) to G2 to mitosis
(M) are provided by the tight regulation maintained
from ubiquitin-mediated proteasome degradation.
The mechanism of NO-mediated p21 upregula-
tion has not been clearly defined. Possible mecha-
nisms include the upregulation of p21 messenger
RNA (mRNA) levels, p21 protein expression, or
both. We studied this question in cultured VSMCs
and found that although p21 mRNA levels are
increased early, preventing this increase with tran-
scriptional inhibitors did not prevent the overall
increase in p21 protein expression by NO. In addi-
tion to the ability of NO to affect steady-state
mRNA levels of p21, we found that NO prevented
the degradation of p21, possibly through the inhibi-
tion of p21 phosphorylation and ubiquination.
METHODS
Cell culture. Rat aortic smooth muscle cells
(RASMCs) from Sprague-Dawley rats (Harlan,
Indianapolis, Ind) were cultured from explanted
thoracic aortas, as described in an earlier study.12
Cultured cells had the characteristic hills and valleys
appearance and were routinely more than 95% pure
by SMC α-actin staining. Cells were grown in
Dulbecco’s Modified Eagles media (low glu-
cose)/Ham’s F12 (1:1 vol:vol; BioWhittaker;
Walkersville, Md) supplemented with 10% fetal
bovine serum, 100 U/mL penicillin, 100 µg/mL
streptomycin, and 4 mmol/L L-glutamine and
maintained in a 37°C, 95% air/5% CO2 incubator.
RASMCs (passages 3 to 8) were plated onto 10-cm
tissue culture dishes. Twenty-four hours after 
plating, the cells were treated with S-nitroso-N-
acetylpenicillamine (SNAP)13 for the designated
times. For some experiments, the cells were pre-
treated for 15 minutes with the phosphatase
inhibitors calyculin A (Sigma, St. Louis, Mo) or 
cantharidin (Sigma), or the transcriptional inhibitors
α-amanitin (Sigma) or actinomycin D (Sigma).
Adenoviral vectors. The human iNOS comple-
mentary DNA (cDNA) was cloned from cytokine-
stimulated human hepatocytes.14 An E1 and E3
deleted adenoviral vector carrying the human iNOS
cDNA (AdiNOS) was designed and constructed as
described in earlier studies.15,16 The titer of AdiNOS
was approximately 109 plaque forming units (PFU)
per milliliter. The titer of the control adenovirus car-
rying the β-galactosidasegene (Adlac Z) was approx-
imately 1011 PFU/mL.
Transduction of rat aortic smooth muscle
cells in vitro. RASMCs (passages 3 to 8) were plat-
ed onto 10-cm tissue culture dishes for 24 hours.
The cells were rinsed with Hanks Balanced Salt
Solution (Gibco, Grand Island, NY), then infected
for 4 hours at 37°C with AdlacZ or AdiNOS by
using a multiplicity of infection (MOI) of 10. This
MOI was chosen based on earlier experiments,
which demonstrated a level of nitrite production
that was not associated with toxicity to the VSMCs
by means of trypan blue exclusion and propidium
iodide staining with FACS analysis for the hypo-
diploid (fragmented) DNA content. Immediately
after infection, cells were serum-starved for an addi-
tional 24 hours. The cells were then treated with
media containing 10% fetal bovine serum for the
indicated times. Because unstimulated RASMCs do
not possess a functional biosynthetic pathway 
for the essential NOS co-factor, tetrahydrobiopterin
(BH4),18,19 exogenous BH4 (10 µmol/L) was 
added to the culture medium to optimize iNOS
activity. The NOS inhibitor, L-N5-(1-iminoethyl)-
ornithine dihydrochloride (L-NIO 1 mmol/L;
Alexis), was added to some treatment groups. To
estimate NO synthesis after adenoviral infection,
nitrite (NO2-) accumulation was assayed with the
Griess reaction.20
Western blot analysis. RASMCs were collected
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at several points after treatment by means of 
scraping and were resuspended in buffer A (20
mmol/L Tris with 100 µmol/L phenylmethyl-
sulfonylflouride [Sigma], 1 µmol/L leupeptin
[Sigma], and 1 µmol/L sodium orthovanadate
[Sigma]). Protein concentration was quantified 
with the BCA protein assay (Pierce, Rockville, Ill).
Whole cell samples (30 µg) were subjected 
to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis on 13% gels and transferred to nitrocel-
lulose membranes (Schleicher and Schuell, Keene,
NH), as described in an earlier study.12 Membranes
were hybridized with either a rabbit polyclonal anti-
p21 antibody (1:1000; Santa Cruz, Santa Cruz,
Calif) or a rabbit polyclonal anti-Ubiquitin antibody
(1:1000; Santa Cruz), followed by horseradish per-
oxidase-linked goat anti-rabbitIgG (1:10,000;
Pierce). Proteins were visualized by using enhanced 
chemiluminescent reagents, according to the manu-
facturer’s instructions (Supersignal Substrate, Pierce).
Immunoprecipitations. RASMCs were collect-
ed as described. Whole cell preparations (100 µg)
were lysed by means of the freeze-thaw technique.
After centrifugation, the cytosol was incubated with
a rabbit polyclonal anti-p21 antibody (10 µg, Santa
Cruz) for 1 hour at 4°C. Protein G Sepharose (5
mg/mL) was then added, and the samples were
incubated overnight at 4°C. The samples were cen-
trifuged, and the pellet was washed with buffer A,
resuspended in sample buffer, boiled for 5 minutes,
and loaded on 13% sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis, as described. The rel-
ative density of the signal was determined by using
Un-Scan-It software (Silk Scientific, Orem, Utah).
Northern blot analysis. Total RNA was extract-
ed from RASMCs with RNAzol reagent by using a
modified method of Chomczynski.21 Total RNA
(20 µg) was electrophoresed on a 1% formaldehyde-
agarose gel and transferred to a nylon membrane
(NEN, Boston, Mass). The membrane was then
hybridized with 32P-labeled cDNA probes of rat p21
and 18S as a control. Hybridized signals were mea-
sured by means of scanning densitometry, and p21
mRNA levels were normalized relative to the 18S
mRNA levels.
Phosphatase assay. RASMCs were collected by
means of scraping and were resuspended in buffer A
without the presence of sodium orthovanadate.
Samples (50 µg) were incubated in an assay buffer
(50 mmol/L Tris-Hcl, 1 mmol/L Na2EDTA, 5
mmol/L dithiothreitol, 0.01% Brij 35, and 1
mg/mL BSA) with 10 µL of substrate for 10 minutes
at 30°C. The reaction was terminated with 20% tri-
cyclic antidepressant, the samples were centrifuged,
and the supernatant was placed in 3 mL of scintilla-
tion fluid and the released 32P quantified. The sub-
strate for the protein tyrosine phosphatase (PTP)
assay (New England Biolabs, Beverly, Mass) was 32P-
labeled myelin basic protein using Abl protein tyro-
sine kinase to phosphorylate specific tyrosine
residues. The substrate for the protein serine/threo-
nine phosphatase (PSP) assay (New England Biolabs,
Beverly, MA) was 32P-labeled myelin basic protein
using cAMP-dependent protein kinase to phospho-
rylate specific serine and threonine residues. The final
specific activity of the protein phosphatases was cal-
culated taking into account released, total, and back-
ground cpm.
Statistical analysis. Results are expressed as the
mean plus or minus SEM. Differences between
groups were analyzed with one-way analysis of vari-
ance with the Student-Newman-Keuls post hoc test
for all pairwise comparisons (SigmaStat; SPSS,
Chicago, Ill). Statistical significance was assumed
when the P value was less than .05.
RESULTS
Nitric oxide upregulates p21 protein expres-
sion. We have previously shown that adenoviral
mediated gene transfer of iNOS to RASMCs dra-
matically increases p21 protein expression at 24
hours.8 Other studies have shown that NO-donors
induce similar levels of p21 upregulation.9 In 
this study, NO released from the NO-donor, SNAP,
induced a time- and concentration-dependent up-
regulation of p21 by means of Western blot analysis
in RASMCs (Fig 1A). The earliest point at which
p21 upregulation was detected after SNAP (0.5
mmol/L) treatment was 6 hours. This increase in
p21 protein expression peaked at approximately 12
to 18 hours and declined thereafter (Fig 1A). The
increase in p21 expression correlated with increasing
SNAP concentration at 6 hours (Fig 1B). However,
as little as 0.125 mmol/L of SNAP resulted in an
increase in p21 levels (Fig 1B). For most of the sub-
sequent experiments, RASMCs were treated with
0.5 mmol/L of SNAP at the 6-hour point, unless
otherwise stated.
Nitric oxide increases p21 messenger RNA
levels at early points. To determine whether NO
was altering steady-state p21 mRNA levels, we
examined RASMCs after exposure to 0.5 mmol/L
of SNAP at both 6 and 24 hours and after AdiNOS
infection by using Northern blot analysis. At 6
hours, SNAP induced a significant increase in the
p21 mRNA levels (control, 1.97 ± 0.22; SNAP, 4.62
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Fig 1. The nitric oxide-donor, S-nitroso-N-acetylpenicillamine (SNAP), induced a time- and
concentration-dependent increase in the expression of p21 protein in cultured rat aortic
smooth muscle cells by means of Western blot analysis. A, SNAP 0.5 mmol/L. B, Time = 6
hours. Data are representative of four similar experiments.
± 0.45; P < .001; Fig 2A). However, by 24 hours,
p21 mRNA levels decreased to levels similar to con-
trol cells (control, 2.53 ± 0.25; SNAP, 3.71 ± 0.31;
P = .07; Fig 2A). NO produced endogenously by
RASMCs after infection with AdiNOS displayed a
trend toward increasing p21 mRNA levels, but this
did not reach statistical significance (control, 5.62 ±
0.07; AdiNOS, 10.57 ± 1.33; P = .09; Fig 2B).
Transcriptional inhibition prevents nitric
oxide-induced upregulation of p21 messenger
RNA, but not p21 protein expression. To deter-
mine whether the early upregulation of p21 mRNA
could account for the increase in p21 protein levels
observed after treatment with SNAP for 6 hours,
RASMCs were pretreated with the transcription
inhibitors α-amanitin or actinomycin D before
SNAP treatment. Parallel experiments were collect-
ed for both Northern blot analysis and Western blot
analysis for p21 mRNA and protein levels, respec-
tively. RASMCs exposed to α-amanitin displayed a
dose-dependent inhibition of p21 mRNA upregula-
tion by SNAP, as did cells exposed to actinomycin D
(Fig 3). However, the upregulation of p21 protein
expression by SNAP was not prevented by either of
these transcription inhibitors (Fig 3). 
Nitric oxide exposure is associated with less
of the ubiquinated form of p21 at both early and
late points. The NO-dependent increase in p21
protein expression in RASMCs could not be entire-
ly explained by an upregulation in p21 mRNA lev-
els. Therefore, we examined the effect of NO on
p21 protein degradation through the ubiquitin-pro-
teasome pathway. Ubiquination of p21 was deter-
mined by immunoprecipitating p21 protein, fol-
lowed by Western blot analysis with an anti-ubiqui-
tin antibody. To take into account changes in total
p21 protein levels, the relative amount of ubiquinat-
ed p21 (Ub-p21) was expressed as a ratio of Ub-
p21/p21. At both early (6-hour) and late (24-hour)
points, treatment with SNAP reduced the relative
proportion of Ub-p21 by approximately 50%, as
compared with control groups (47% decrease at 6
hours, P = .017; 40% decrease at 24 hours, P = .011;
Fig 4A). Similarly, NO production after iNOS gene
transfer was associated with approximately half as
much of the ubiquinated form of p21, compared
with the noninfected cells (60% decrease AdiNOS vs
control, P = .010; Fig 4B). We did note, however,
that after adenoviral gene transfer of β-galactosidase,
there was a slight increase in p21 protein expression,
and this was associated with less ubiquinated p21
(Fig 4B). Hence, adenoviral gene transfer may inde-
pendently affect the ubiquitin-proteasome pathway.
Nitric oxide stimulates both protein ser-
ine/threonine and protein tyrosine phosphatase
activity. Mechanisms by which NO may reduce the
levels of ubiquinated p21 could involve inhibition
of the kinases involved in phosphorylating p21,
which would target it for ubiquination and degrada-
tion, or it could involve the activation of phos-
A
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phatases that remove the targeting phosphate on
p21, thus preventing ubiquination and degradation.
Other mechanisms could include interaction with
the ubiquitin enzymes involved in placing the poly-
ubiquitin chain on p21 or interfering with the actu-
al function of the 26S proteasome. Because the spe-
cific kinase involved in phosphorylating p21 for
ubiquination has not been identified, we examined
the effect of NO on the two major classes of phos-
phatases, tyrosine and serine/threonine. After expo-
sure to SNAP, there was a concentration-dependent
increase in the protein serine/threonine phosphatase
activity at 2 and 6 hours (Fig 5A). Phosphatase
activity was greater at the 2-hour point. Protein
tyrosine phosphatase activity was also found to
increase in a concentration-dependent manner after
exposure to SNAP at both 2 and 6 hours (Fig 5B).
However, at very high concentrations of SNAP (1.0
mmol/L), there was a reduction in activity, com-
pared with SNAP at the level of 0.5 mmol/L. Thus,
NO activates both serine/threonine and tyrosine
phosphatase activity in VSMCs.
Phosphatase inhibitors prevent the nitric
oxide-dependent upregulation of p21 protein
expression. After demonstrating that NO increased
serine/threonine and tyrosine phosphatase activity,
we wanted to determine the effect of inhibiting
phosphatase activity on NO-induced p21 expres-
sion. Calyculin A is a cell-permeable inhibitor of
protein serine/threonine phosphatases PP2A (IC50
= 1 nmol/L) and PP1 (IC50 = 2nM). Cantharidin is
also a cell permeable inhibitor of PP2A (IC50 = 40
nmol/L) and PP1 (IC50 = 473 nmol/L). Calyculin
A, in concentrations ranging from 1 to 10 nmol/L,
inhibited both basal and SNAP-induced serine/thre-
onine phosphatase activity 6 hours after treatment
(Fig 6A). Cantharidin in concentrations ranging from
1 to 10 mmol/L also inhibited basal and SNAP-
Fig 2. Nitric oxide increases p21 messenger RNA (mRNA) levels in rat aortic smooth muscle
cells after exposure to S-nitroso-N-acetylpenicillamine (SNAP) at an early point. A, Rat aortic
smooth muscle cells were exposed to media or media containing SNAP (0.5 mmol/L) for the
indicated times. The cells were collected, and the mRNA was subjected to Northern blot analy-
sis. SNAP increased the steady-state levels of p21 mRNA after exposure to SNAP for 6 hours
(*P < .001 vs control). There was no statistically significant difference at 24 hours. B, Cultured
rat aortic smooth muscle cells were infected with adenoviral vectors encoding either β-galac-
tosidase (AdlacZ) or human inducible nitric oxide synthase complementary DNA (AdiNOS;
multiplicity of infection = 10). After 24 hours of nitric oxide production, the cells were col-
lected, and the mRNA was subjected to Northern blot analysis. AdiNOS-infected cells dis-
played a trend toward increased p21 mRNA levels, but this was not statistically significant.
Densitometry data for p21 were normalized by 18S. Photomicrographs represent one of three
independent experiments. Graphs represent the data from all three independent experiments.
A B
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induced serine/threonine phosphatase activity (Fig
6A). Treatment of RASMCs with either calyculin A or
cantharidin prevented the NO-mediated upregulation
of p21 protein in a concentration-dependent manner.
However, only at concentrations of calyculin A or
cantharidin that reduced the overall phosphatase
activity significantly below baseline did we observe the
inhibition of NO-induced p21 expression. These data
provide evidence implicating phosphatases in the
reduction in p21 degradation (Fig 6B).
DISCUSSION
NO has been shown to reduce intimal hyperpla-
sia in both rodent and porcine models of vascular
injury.16,22 The mechanisms by which NO inhibits
this vascular healing response are manifold, but the
predominant mechanism is believed to be related to
its antiproliferative actions on VSMCs. In this study,
we show that VSMCs exposed to endogenous and
exogenous sources of NO production exhibit an
increase in the expression of the cell cycle inhibitor
p21. This supports previous work from our labora-
tory and published studies from other investiga-
tors.8,9 A number of cell cycle proteins have been
reported to also be regulated by NO. These include
cyclin A, cyclin B, cyclin D, cyclin E, cdc2, cdk2,
p27, and p53.8,9,23-27 We have focused our efforts
on p21 because it is a universal inhibitor of the cell
cycle, interacting with cyclins and cdks in all phases
of the cell cycle. Overexpression of p21 has been
reported to inhibit VSMC proliferation in vitro and
reduce intimal hyperplasia in vivo.28-30 These results
suggest that NO-mediated inhibition of VSMC pro-
liferation and the upregulation of p21 protein levels
are linked in that one mechanism by which NO
inhibits VSMC proliferation is through the induc-
tion of cell cycle inhibitors such as p21. 
Although numerous reports indicate that NO
can upregulate p21, the mechanisms involved have
not been identified. Our results point to two mech-
anisms. First, there is an early increase in p21 mRNA
levels. However, this is transient, and more impor-
tant, protein levels increased even in the presence of
transcriptional inhibitors that blocked the increase in
mRNA levels. Therefore, we focused on the second
mechanism, an increase in p21 protein stability.
Turnover of cell cycle proteins has been demon-
strated to be regulated by the ubiquitin-proteasome
pathway. Examples of such proteins include cyclin A,
cyclin B, cyclin D, cyclin E, p21, p27, p57, p53,
E2F, cdc25, c-myc, c-jun, and c-fos.11,31 The ubiq-
uitin-proteasome pathway is composed of several
steps (for reviews, see references 11 and 32 to 35).
First, proteins targeted for degradation are marked
by phosphorylation. The exact kinases involved in
this process remain largely unidentified. These phos-
phorylated proteins then become targets for ubi-
quination through the coordinated actions of the
ubiquitin activating enzyme (E1), ubiquitin conju-
gating enzyme (E2), and ubiquitin ligase (E3). This
process ultimately leads to the transfer of polyubiq-
uitin chain(s) to lysine residues on the phosphory-
lated moieties. Finally, these ubiquinated proteins
are recognized by the 26S proteasome as substrates
for proteolysis. Regulation of the cyclin-dependent
kinase inhibitor p27 by the ubiquitin-proteasome
pathway has been well characterized.36 Similar data
exist for the regulation of p21 by the ubiquitin-pro-
teasome pathway.37,38 Therefore, changes in protein
degradation rates represent a common mechanism
for the regulation of proteins involved in controlling
the cell cycle, and it may not be surprising that NO
functions through this mechanism.
We present evidence that NO treatment of
VSMCs results in a relative reduction in the levels of
ubiquinated p21 protein, as compared with untreat-
ed VSMCs, suggesting that increases in p21 protein
Fig 3. Transcription inhibitors prevent nitric oxide-
induced upregulation of p21 messenger RNA (mRNA)
levels, but not p21 protein expression. Rat aortic smooth
muscle cells were pretreated with the transcription
inhibitors α-amanitin or actinomycin D, followed by
exposure to S-nitroso-N-acetylpenicillamine (SNAP) for
6 hours. It was revealed by means of Northern blot analy-
sis that both α-amanitin and actinomycin D prevented the
SNAP-induced upregulation of p21 mRNA levels; how-
ever, the upregulation of p21 protein expression by SNAP
was not affected by either transcription inhibitor.
Northern and Western blot analyses were performed on
parallel experiments. Data are representative of two inde-
pendent experiments.
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levels result in part from a reduction in p21
turnover. This inhibition of ubiquination of p21 was
detected when either exogenous or endogenous
sources of NO were used. The role NO plays in pre-
venting the ubiquination of p21 may involve the
activation of protein phosphatases, because inhibi-
tion of serine/threonine phosphatases with calyculin
A or cantharidin to levels below baseline inhibited
the upregulation of p21 protein expression by NO.
One explanation for why we do not see the inhibi-
tion of NO-induced upregulation of p21 until the
phosphatase inhibitors reduce phosphatase activity
well below baseline is that these inhibitors affect cer-
tain phosphatases more than others. Thus, although
overall serine/threonine phosphatase activity is
affected to a certain level, the specific phosphatase
affected by NO may not have been affected to a sim-
ilar degree. Regardless, these results suggest that
NO may upregulate protein phosphatases, which
remove the phosphate groups intended to mark p21
protein for proteolysis (Fig 7).
Although we provide direct evidence for the acti-
vation of both serine/threonine and tyrosine phos-
phatase activity by NO, the evidence linking the acti-
vation of these phosphatases to the ability of NO to
prevent the ubiquination of p21 is indirect, through
the use of these phosphatase inhibitors. More direct-
ly determining the role of the phosphatase(s) acti-
vated by NO in this process would require specific
reagents to the different cellular phosphatases.
Currently, this is a limiting factor in carrying out
these more definitive experiments. Hence, the iden-
tification of which specific phosphatase(s) are being
activated by NO and the ability to more directly link
their activation to the prevention of ubiquination of
p21 awaits further investigation.
Fig 4. Nitric oxide decreases the level of ubiquinated p21 in rat aortic smooth muscle cells at
both early and late points. Rat aortic smooth muscle cells were immunoprecipitated with an
anti-p21 polyclonal antibody and subjected to Western blot analysis for both p21 and ubiqui-
tin. A, S-nitroso-N-acetylpenicillamine (SNAP; 0.5 mmol/L) treatment was associated with a
marked upregulation of p21 expression, compared with control treated cells at both 6 and 24
hours. This was associated with a statistically significant decrease in the level of ubiquinated
p21 (*P = 0.017 vs control at 6 hours; **P = .011 vs control at 24 hours). B, Rat aortic
smooth muscle cells infected with adenoviral vectors encoding either β-galactosidase (AdlacZ)
or human inducible nitric oxide synthase complementary DNA (AdiNOS; multiplicity of infec-
tion = 10) were collected after exposure to nitric oxide for 24 hours. iNOS gene transfer result-
ed in a significant decrease in the expression of ubiquinated p21 (*P = .010 vs control).
Photomicrographs represent one of four independent experiments. Graphs represent the den-
sitometry data from all four independent experiments. Levels of ubiquinated p21 were nor-
malized to total p21 signal.
A B
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 2 Kibbe et al 371
It is also possible that NO upregulates p21
through other mechanisms. As we demonstrated in
Fig 2, NO is able to upregulate steady-state p21
mRNA levels. However, with the inhibition of this
upregulation, NO was still able to increase p21 pro-
tein expression. Thus, we conclude that NO is able
to upregulate the expression of p21 through at least
two different mechanisms, an increase in p21 mRNA
levels and prevention of p21 ubiquination and
degradation. Although our results suggest that NO
inhibits p21 degradation, we have not ruled out
other possibilities, including an effect on translation
or through regulation of other proteins involved in
control of the cell cycle or the ubiquitin-proteasome
pathway. For example, the effect of ubiquination
may involve the action of NO on one of the ubiqui-
tin activating, conjugating, or ligase enzymes. NO
may also inhibit the activity of the actual kinase that
phosphorylates p21 and targets it for degradation.
As the specificity of these enzymes are uncovered,
analysis of these aspects of the degradation process
will be more amenable to investigation. Overall, the
expression of cell cycle proteins can involve multiple
levels of regulation, and we present evidence in this
manuscript that NO is able to affect p21 expression
levels through at least two different mechanisms.
One aspect of the data analysis in this manuscript
that should be addressed is the method we used to
quantitate the levels of Ub-p21, specifically report-
ing the relative levels of Ub-p21 to total p21. NO
Fig 5. Nitric oxide increases protein serine/threonine and protein tyrosine phosphatase activ-
ity. Rat aortic smooth muscle cells were exposed to increasing concentrations of S-nitroso-N-
acetylpenicillamine (SNAP) for 2 or 6 hours. Cell lysate was collected and assayed for phos-
phatase activity by using phosphorylated myelin basic protein as the substrate. SNAP induced
a concentration-dependent increase in A, protein serine/threonine phosphatase activity at
both 2 (*P = .046 vs control) and 6 hours (*P < .001 vs control), and in B, protein tyrosine
phosphatase activity at both 2 (*P = .008 and **P = .014 vs control) and 6 hours (*P = .026
vs control). Data represent one of four independent experiments (n = 3 per group).
A B
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Fig 6. Phosphatase inhibitors prevent the upregulation of p21 by nitric oxide. Rat aortic smooth
muscle cells were treated with S-nitroso-N-acetylpenicillamine (SNAP; 0.5 mmol/L) with or with-
out calyculin A (CaA) and with or without cantharidin (Canth). Whole cell lysate was collected
after treatment for 6 hours. A, Both calyculin A (upper panel; *P < .001 vs control; #P < .001 vs
SNAP) and cantharidin (lower panel; *P < .001 vs control; **P = .02; #P < .001 vs SNAP) inhib-
ited basal and SNAP-induced protein serine/threonine phosphatase activity. B, It was revealed by
means of Western blot analysis that calyculin A and cantharidin prevented the SNAP-induced
upregulation of p21 in a concentration-dependent manner. Data are representative of four identi-
cal experiments; n = 3 per group for the phosphatase assay.
A
B
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increases total p21 protein expression without sig-
nificantly affecting the ubiquination rate of p21. If
the rate of ubiquination of p21 were constant, we
would expect the levels of Ub-p21 to increase with
exposure to NO. However, we found no significant
change in the absolute levels of Ub-p21, whereas the
total expression of p21 is significantly increased.
This indicates that NO blocks further ubiquination
of the upregulated p21 and that the relative ratio of
Ub-p21 to total p21 reflects the dynamics of upreg-
ulation and degradation of p21. There still may be
alternative interpretations of the data. For example,
NO may be affecting one of the deubiquinating
enzymes; however, in that case, we would expect to
see a decrease in the absolute level of Ub-p21.
Additionally, NO may be affecting the function of
the 26S proteasome itself. However, the most likely
explanation for our data is that NO is able to upreg-
ulate p21 expression through both an increase in
p21 mRNA levels and through prevention of its
ubiquination and degradation by the ubiquitin-pro-
teasome pathway.
It is possible that NO also upregulates p21, in
part, by increasing mRNA levels short-term, but for
prolonged upregulation of p21 expression, other
mechanisms, such as preventing the degradation of
p21 by the ubiquitin-proteasome pathway, may be
affected. Our experiments with iNOS gene transfer
resulted in no upregulation of p21 mRNA levels.
This suggests that increases in transcription or
mRNA stability are not likely to be dominant mech-
anisms. SNAP did increase mRNA levels at an early
point. The differences between SNAP and iNOS
gene transfer on mRNA levels may be explained by
the NO exposure patterns resulting from each
method, with SNAP leading to short high-level
exposure and iNOS transfer resulting in sustained
low-level exposure. Both methods of NO exposure
lead to an increase in p21 protein and decreased
ubiquination, again pointing to this as a potentially
more dominant regulatory mechanism.
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